A phase IIa multiple basket study (Mypathway) also demonstrated a moderate efficacy of dual blockade with trastuzumab and pertuzumab in HER2-altered NSCLC patients (47). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.